# Cabenuva Kit (cabotegravir; rilpivirine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cabotegravir-rilpivirine

> The FDA approved Cabenuva Kit (cabotegravir; rilpivirine), sponsored by GSK plc (GSK), on January 21, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Cabenuva Kit (cabotegravir; rilpivirine) |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | priority review |

## Timeline

### December 19, 2019: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22212887Orig1s000%2C212888Orig1s000OtherActionLtrs.pdf%22

### January 21, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212888 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20210121, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product CABENUVA KIT (CABOTEGRAVIR; RILPIVIRINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212888%22

### January 31, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212888 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20220131, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product CABENUVA KIT (CABOTEGRAVIR; RILPIVIRINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212888%22
- openFDA Drugs@FDA: "NDA212888 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20220207, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product CABENUVA KIT (CABOTEGRAVIR; RILPIVIRINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212888%22

### March 23, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212888 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20220323, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product CABENUVA KIT (CABOTEGRAVIR; RILPIVIRINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212888%22
- openFDA Drugs@FDA: "NDA212888 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20220329, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product CABENUVA KIT (CABOTEGRAVIR; RILPIVIRINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212888%22
- openFDA Drugs@FDA: "NDA212888 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20220329, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product CABENUVA KIT (CABOTEGRAVIR; RILPIVIRINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212888%22

### September 20, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212888 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20240920, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product CABENUVA KIT (CABOTEGRAVIR; RILPIVIRINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212888%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cabotegravir-rilpivirine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cabenuva Kit (cabotegravir; rilpivirine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cabotegravir-rilpivirine

```bibtex
@misc{secapidev_pdufa_cabotegravir_rilpivirine_20261116,
  title        = {Cabenuva Kit (cabotegravir; rilpivirine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cabotegravir-rilpivirine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cabotegravir_rilpivirine_20261116","title":"Cabenuva Kit (cabotegravir; rilpivirine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cabotegravir-rilpivirine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
